Search

Recent studies from the University of Freiburg in Germany have explored the role of histone deacetylase 3 (HDAC3) in maintaining queen-like characteristics in termites. The research suggests that silencing HDAC3 leads to signals indicative of queen hallmarks, such as increased fecundity and longevity. This study sheds light on the epigenetic mechanisms that regulate caste polyphenism in social insects, providing insights into the extraordinary lifespans and high fecundity of termite queens. [Extracted from the article]

A recent study conducted at the Pennsylvania Biotechnology Center has found that drugs targeting the enzyme Sirtuin 2 (SIRT2) exhibit broad-spectrum anti-infective activity. Unlike traditional anti-infective drugs that target specific pathogens, SIRT2-targeted drugs have the potential to overcome resistance and inhibit the replication of both RNA and DNA viruses, as well as intracellular bacterial pathogens. These drugs act as allosteric modulators and impact the replication cycles of intracellular pathogens at multiple levels. Further research is needed to explore the pharmacological action of these drugs and their potential as anti-infective agents in clinical settings. [Extracted from the article]

A preliminary study conducted by researchers at Zhejiang University School of Medicine explores the role of sirtuin-1 (SIRT1) in senescence and inflammation in abdominal aortic aneurysms (AAA). The study used angiotensin II (Ang II) to induce AAA in human aortic vascular smooth muscle cells (HASMCs) and evaluated the effects of SIRT1 on senescence and inflammation. The results showed that overexpression of SIRT1 reduced inflammatory and senescent responses in the AAA cell model induced by Ang II. This suggests that SIRT1 could be a promising target for clinical treatment of AAA. [Extracted from the article]

A recent study conducted in Liaoning, China, has identified a protein called Zinc Finger Miz-type containing 2 (ZMIZ2) as an oncoprotein that enhances the activity of the NAD-dependent protein deacetylase Sirtuin-1 (SIRT1) in non-small cell lung cancer (NSCLC). The study found that ZMIZ2 is highly expressed in NSCLC and is associated with advanced staging, lymph node metastasis, and poor overall survival. ZMIZ2 promotes the proliferation, migration, and invasiveness of lung cancer cells by regulating the Wnt/Hippo pathways through its interaction with SIRT1. These findings provide a basis for the development of novel biomarkers and targeted drugs for NSCLC. [Extracted from the article]

A study on biomimetics conducted by researchers at Lewis University in Romeoville, Illinois, explores the coordination of 8-hydroxquinoline inhibitors with biomimetic zinc complexes and human histone deacetylase 8 (HDAC8), a monozinc hydrolase enzyme. The researchers aimed to analyze the structural and electronic characteristics of 10 8-hydroxquinoline derivatives and their inhibition efficacy. The study highlights the complexities of inhibitor-zinc enzyme interactions and suggests the importance of intricate noncovalent interactions for ligand binding to enzymes. The research provides insights into the therapeutic potential of zinc-binding ligands in the treatment of cutaneous T-cell lymphoma. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the role of histone deacetylase 5 (HDAC5) in the prelimbic (PrL) and infralimbic (IL) cortices in context-associated cocaine seeking. The study used rat models and various molecular tools to investigate the molecular mechanisms behind the formation of prepotent drug-context associations. The findings suggest that HDAC5 in the PrL plays a selective role in limiting associations formed in cocaine self-administration environments, possibly through the epigenetic regulation of synaptic genes. However, further research and peer-review are needed to validate these findings. [Extracted from the article]

A recent study conducted at Zhejiang Hospital in China explored a potential therapeutic strategy for B-cell lymphoma. The study focused on combining a histone deacetylase inhibitor (romidepsin) with PD-1 blockade (BMS-1) in a mouse model of B-cell lymphoma. The results showed that the combined treatment of romidepsin and BMS-1 synergistically inhibited the growth of B-cell lymphoma and triggered apoptosis. Additionally, the treatment activated tumor-infiltrating lymphocytes, particularly CD3+CD4+ and CD3+CD8+ T cells. The study suggests that the combination of HDAC inhibition and PD-1 blockade could be a promising approach for treating B-cell lymphoma and enhancing antitumor immunity. [Extracted from the article]

A study conducted by Istanbul University-Cerrahpasa has found that preconditioning human umbilical cord mesenchymal stem cells (MSCs) with the histone deacetylase inhibitor valproic acid (VPA) enhances the activity of the MSCs and modifies their secretome content. MSCs are important in regenerative medicine due to their ability to differentiate into multiple cell lines and regulate the immune system. Preconditioning techniques, such as the use of pharmacological agents like VPA, can improve the therapeutic potential of MSCs. The study found that VPA treatment increased protein secretion, particularly nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), and induced cytoskeletal rearrangement and autophagic activity, suggesting the initiation of neuronal differentiation. [Extracted from the article]

A new study conducted at the University of Miami explores the molecular mechanisms of HIV-related chronic pain. The research focuses on the role of the transcription factor cMyc, epigenetic writer enhancer of zeste homology 2 (EZH2), and sirtuin 3 (Sirt3) pathway in neuropathic pain induced by HIV glycoprotein gp120 with morphine. The study found that the decrease in spinal Sirt3 in this pain model was mediated by cMyc-EZH2/H3K27me3 activity in an epigenetic manner. These findings provide new insights into the mechanisms of neuropathic pain in HIV patients using chronic opioids. [Extracted from the article]

A recent study conducted by researchers at the Second Affiliated Hospital of Fujian Medical University in China has found that omega-3 polyunsaturated fatty acids (o-3 PUFAs) can alleviate neuroinflammation caused by endoplasmic reticulum (ER) stress in spinal cord injury (SCI). The study focused on the interaction between o-3 PUFAs and organelles, specifically the histone deacetylase 3 (HDAC3)/peroxisome proliferator-activated receptor-g coactivator (PGC)-1 pathway. The researchers discovered that o-3 PUFA treatment reduced ER stress, decreased HDAC3 expression levels and inflammatory responses, and increased PGC-1 expression levels. These findings suggest that o-3 PUFAs may have a role in protecting against SCI-induced neuroinflammation and promoting neurological functional recovery. [Extracted from the article]

A new report from the University of Texas MD Anderson Cancer Center discusses the challenges of treating breast and ovarian cancers. The researchers explored the synergistic effects of combining histone deacetylase inhibitors (HDACis), poly(ADP-ribose) polymerase inhibitors (PARPis), and decitabine in breast and ovarian cancer cell lines. The combinations of these drugs showed synergistic cytotoxicity in all cell lines, inhibiting cell proliferation and inducing DNA damage. The researchers suggest that further exploration and clinical validation of these combinations are needed to assess their safety and efficacy in treating these types of tumors. [Extracted from the article]

A recent study conducted by researchers at Columbia University has found that a combination of two drugs, romidepsin and afatinib, shows promising results in treating cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas are a type of cancer that affects the skin-resident T-cells. While current treatments using histone deacetylase inhibitors are effective, they are not curative. The combination of romidepsin and afatinib was found to have strong synergistic antitumor effects by inhibiting Jak-signal transducer and activator of transcription signaling. This research suggests a potential new treatment option for cutaneous T-cell lymphomas. [Extracted from the article]

Researchers from the University of Baghdad have conducted a study on nucleoproteins, specifically focusing on developing new histone deacetylase (HDAC) inhibitors with a thiadiazole moiety as a zinc-binding group. The researchers used Maestro software to design these inhibitors and synthesized them through organic synthesis. The compounds were characterized using spectroscopic techniques and were found to have in silico binding affinity for HDAC enzymes. Preliminary cytotoxicity evaluation showed promising results, suggesting that these compounds could be potential therapeutic agents. The full study can be found in the Tropical Journal of Pharmaceutical Research. [Extracted from the article]

A recent study conducted in Guangdong, China, explored the role of histone deacetylase 4 (HDAC4) in sepsis-induced alveolar epithelial cell injury. The researchers found that HDAC4 expression increased in cells stimulated by lipopolysaccharide (LPS), a component of bacterial cell walls. Silencing HDAC4 inhibited inflammatory damage, reduced oxidative stress, decreased cell apoptosis, improved mitochondrial function, and blocked the c-Jun N-terminal kinase (JNK)/activating protein-1 (AP-1) signaling pathway. These findings suggest that interfering with HDAC4 could potentially ameliorate sepsis-induced alveolar epithelial cell injury through the JNK/AP-1 signaling pathway. Further research is needed to explore this potential therapeutic target. [Extracted from the article]

Researchers at the Medical College of Wisconsin have conducted a study on the role of histone deacetylase 6 (HDAC6) in myocardial ischemia/reperfusion injury (MIRI) in diabetic mice. The study found that diabetes increases HDAC6 activity and the production of tumor necrosis factor alpha (TNF-alpha), leading to mitochondrial injury and impaired cardiac function. However, genetic deletion or pharmacologic inhibition of HDAC6 was shown to protect the heart against MIRI by reducing TNF-alpha-induced mitochondrial injury. This research provides insights into potential therapeutic targets for protecting the heart in individuals with diabetes. [Extracted from the article]

A recent study conducted by researchers at Harbin Medical University in Heilongjiang, China, has provided new insights into the role of mitochondrial proteins in fluoride-induced osteoblastic differentiation. The study found that fluoride promotes the expression of certain proteins, including superoxide dismutase 2 (SOD2) and sirtuin 3 (SIRT3), in osteoblasts. Additionally, the researchers discovered that fluoride suppresses the levels of reactive oxygen species (ROS) and mitochondrial reactive oxygen species (mtROS) in osteoblasts. The study suggests that SIRT3/SOD2 mediates fluoride-promoted osteoblastic differentiation by down-regulating ROS. [Extracted from the article]

A study conducted at National Sun Yat-Sen University in Taiwan investigated the effects of etanercept, a tumor necrosis factor (TNF)-a inhibitor, on osteoarthritis (OA) in rats. The researchers found that etanercept therapy reduced cartilage degeneration and synovitis, improved nociceptive behavior and weight-bearing distribution, and regulated chondrocyte metabolism. The study suggests that etanercept may have therapeutic potential in treating OA. The research was supported by the National Science and Technology Council and Pingtung Christian. [Extracted from the article]

A recent study conducted in Karnataka, India, examined the levels of sirtuin 1 (SIRT1) in patients with diabetic nephropathy. The study compared SIRT1 serum levels in non-insulin dependent diabetics and diabetic nephropathy patients, as well as evaluated the pattern of polymorphism of the SIRT1 gene in these patients. The results showed that diabetic nephropathy patients had significantly lower serum SIRT1 levels compared to controls. However, there was no significant association observed between SIRT1 gene polymorphism and serum SIRT1 levels in diabetic nephropathy patients. The study suggests that further research is needed to better understand the role of SIRT1 in diabetic nephropathy and its potential as a diagnostic marker or therapeutic target. [Extracted from the article]

A recent study conducted by researchers at McGill University in Montreal, Canada, explored the design and synthesis of antiestrogen/histone deacetylase inhibitor (HDACi) hybrids for the treatment of breast cancer. The study aimed to merge the structures of raloxifene and suberoylanilide hydroxamic acid to create these hybrids. Four of the hybrids showed promising results in terms of their antiestrogenic activity and HDAC inhibition. The researchers also demonstrated the antiproliferative activity of these hybrids in both estrogen receptor-positive and estrogen receptor-negative breast cancer cell lines. This research has been peer-reviewed and published in the European Journal of Medicinal Chemistry. [Extracted from the article]

A patent application titled "Cell-Of-Origin Targeted Drug Repurposing For Triple-Negative And Inflammatory Breast Carcinoma With Hdac And Hsp90 Inhibitors Combined With Niclosamide" has been published online. The patent application discusses the challenges of treating breast cancer, particularly triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC), which currently have no targeted therapies. The inventors propose a cell-based approach that leverages the unique features of different normal cell types to develop cell-targeted therapies. They have discovered that a drug approved for treating tapeworm infestation, combined with an antibiotic derivative, can enhance the killing of breast cancer cells. The patent application describes methods for assaying gene expression levels and administering histone deacetylase inhibitors, heat shock protein 90 inhibitors, and helminths to patients with poor prognosis or malignant cancer. The inventors suggest that these drugs could be repurposed to treat breast cancer. [Extracted from the article]

A research study conducted at Zunyi Medical University in China explores the use of histone deacetylase inhibitors (HDACi) in the treatment of acute myeloid leukemia (AML). AML is a type of cancer characterized by the abnormal proliferation of myeloid cells in the bone marrow and other tissues. The study highlights the potential of HDACi to induce differentiation, cell cycle arrest, and apoptosis in AML cells. While HDACi alone may not be as effective as conventional therapy, combining them with other anticancer drugs has shown promising results in clinical trials. The development of selective HDACi with fewer side effects is an area of focus for future research. [Extracted from the article]

A recent study conducted by researchers at the Institute of Biomedical Research in Zhengzhou, China, has found that histone deacetylase 8 (HDAC8) plays a role in promoting innate antiviral immunity by deacetylating the protein RIG-I. The researchers demonstrated that over-expression of HDAC8 inhibited the replication of vesicular stomatitis virus (VSV), while knockdown of HDAC8 promoted VSV replication. The study concluded that HDAC8 enhances innate antiviral immune response by promoting RIG-I mediated interferon production and downstream signaling pathway. This research provides valuable insights into the mechanisms underlying antiviral immune response. [Extracted from the article]

A recent report from the University of Brawijaya in Malang, Indonesia discusses research on nanoprecipitation and its potential application in treating atherosclerosis, a cardiovascular disease caused by endothelial dysfunction. The study focuses on the formulation and characterization of nanoparticles carrying Sirtuin 1 (NPS1) using different solvents. The research aims to develop a method for increasing Sirtuin 1 levels in cells to improve the quality of endothelial progenitor cells (EPC) and prevent premature senescence. The findings suggest that the NPS1 formulation shows promise for anti-senescence therapy in EPC cells and could be further explored in in vitro and in vivo studies. [Extracted from the article]

A recent study conducted by researchers at Islamic Azad University in Iran examined the effects of combined exercise on glucose homeostasis and plasma levels of sirtuin 1 and FOXO1 in obese elderly men. The study involved 40 obese elderly men who were randomly divided into two groups: an experimental group and a control group. The participants in the experimental group underwent 16 weeks of combined exercise training, while the control group did not. The results showed that the exercise intervention led to a significant decrease in fasting blood sugar and insulin levels, as well as a significant increase in the levels of sirtuin 1 and FOXO1. The researchers concluded that 16 weeks of combined exercise training can have a positive effect on improving glucose homeostasis and increasing sirtuin 1 and FOXO1 levels in elderly obese men. [Extracted from the article]

A new report discusses research findings on histone deacetylase inhibitors, specifically focusing on the effects of panobinostat on lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase (iNOS) in rat immortalized microglia cells. The study found that panobinostat inhibited the expression of iNOS mRNA and reduced nitric oxide production in a dose-dependent manner. Additionally, panobinostat inhibited the interferon-beta (IFN-beta)/signal transducer and activator of transcription (STAT) pathway, which is essential for LPS-induced iNOS expression. The researchers concluded that panobinostat's inhibitory effects are not only due to the inhibition of the IFN-beta/STAT axis but also involve the downregulation of other factors. [Extracted from the article]

A recent study conducted by researchers at Ajman University in the United Arab Emirates explored the potential of repurposing FDA-approved drugs as inhibitors for histone deacetylase 3 (HDAC3), a target in the treatment of complex diseases, including cancer. Through structure-based virtual screening and molecular dynamics simulations, the researchers identified two drugs, Imatinib and Carpipramine, that demonstrated strong affinity and specificity for HDAC3. The study suggests that these drugs may hold significant therapeutic potential for the treatment of various diseases, particularly cancer. Further research is needed to explore their efficacy in clinical settings. [Extracted from the article]

A recent study conducted by researchers at the State Research Institute Center for Innovative Medicine in Vilnius, Lithuania, has explored the potential use of class I and II histone deacetylase inhibitors (HDACi) as therapeutic modulators for dilated cardiac tissue-derived mesenchymal stem/stromal cells. The study found that these inhibitors improved acetylation and enhanced the energetic status of the cells, particularly in dilated myocardium-derived cells. Additionally, the HDAC inhibitors activated certain cardiac transcription factors and upregulated structural proteins, suggesting their potential as novel therapeutic interventions for dilated cardiomyopathy. Further research in this area could lead to improvements in heart function. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Lodz in Poland explores the role of histone deacetylases (HDACs) in retinoblastoma, a pediatric ocular malignancy. The dysregulated activity of HDACs has been linked to retinoblastoma pathogenesis, affecting crucial cellular processes such as cell cycle regulation and retinal ganglion cell apoptosis. The study suggests that HDAC inhibitors could potentially restore acetylation balance and impede retinoblastoma progression. The research highlights the potential for personalized therapeutic strategies based on specific HDAC isoforms, offering tailored interventions for individual patients. This study sheds light on the complex interplay between HDACs and retinoblastoma, providing insights into epigenetic mechanisms that control tumor development and progression. [Extracted from the article]

A recent study conducted by researchers at Tohoku University Graduate School of Dentistry in Sendai, Japan, explored the effects of histone deacetylase inhibitors (HDACis) on dental pulp stem cells (DPSCs). The researchers found that the HDACi MS-275 enhanced the matrix mineralization of DPSCs by inducing the expression of fibronectin (FN1). This finding suggests that MS-275 could be used as a therapeutic agent to promote reparative dentin formation by creating a suitable extracellular matrix environment for mineralization. The study provides valuable insights into the potential applications of HDACis in dentistry. [Extracted from the article]

A recent study conducted at Children's Hospital in Cincinnati, Ohio, has found that inhibiting the activity of histone deacetylase (HDAC) can increase the effectiveness of cisplatin in eliminating metastatic cells in pediatric liver cancers. The researchers discovered that cancer-associated fibroblasts (CAFs) and neuron-like cells in the metastatic microenvironments of hepatoblastoma and hepatocellular carcinoma express high levels of HDAC1. By combining HDAC inhibition with cisplatin treatment, the researchers were able to eliminate CAFs and inhibit proliferation in these cancer cells. The study suggests that this combination therapy could be beneficial in treating pediatric liver cancers. [Extracted from the article]

Researchers at Central South University have conducted a study on colorectal cancer (CRC) and identified the dysregulated gene Tweety homolog 3 (TTYH3) as a potential factor in promoting CRC metastasis. The study found that TTYH3 upregulation in CRC promotes cell migration through the Epithelial-mesenchymal transition pathway, independent of its ion channel activity. TTYH3 and histone deacetylase 7 (HDAC7) were found to function as competing endogenous RNAs (ceRNAs), reciprocally regulating each other's expression. This research provides new insights into potential therapeutic targets for clinical intervention in CRC metastasis. [Extracted from the article]

A recent study conducted by researchers at the Mexican Institute for Social Security-IMSS in Zacatecas, Mexico, explores the use of histone deacetylase inhibitors (HDAC inhibitors) to enhance the innate immune response against non-tuberculous mycobacterial infection. The researchers found that certain molecules that bind to the catalytic site of HDAC inhibit its activity, leading to increased expression of cytokines and antimicrobial peptides associated with reducing infection. The study suggests that these HDAC inhibitors could be used as potential treatments for immunocompromised patients with non-tuberculous infections. The research was supported by various funding agencies, including Consejo Nacional De Ciencia Y Tecnologia and Agencia Estatal De Investigacion, Spain. [Extracted from the article]

A recent study conducted by researchers at the Chinese Academy of Medical Sciences explored the use of abexinostat, an oral histone deacetylase inhibitor, in patients with relapsed/refractory follicular lymphoma (FL). The study found that abexinostat was well-tolerated and showed significant response in patients with heavily pretreated FL. The primary endpoint of the study was the overall response rate (ORR), and secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. The study concluded that abexinostat has potential as a treatment option for patients with relapsed/refractory FL. [Extracted from the article]

A recent study conducted at the Pennsylvania Biotechnology Center has investigated the antiviral properties of a newly described allosteric modulator, FLS-359, that targets sirtuin 2 (SIRT2) in relation to hepatitis B virus (HBV) infection. The study found that FLS-359 inhibits the synthesis of covalently closed circular DNA (cccDNA) and reduces cccDNA recycling, impairing its transcriptional activity. The research suggests that SIRT2 inhibitors could be developed as effective antivirals for HBV. The study was supported by the National Institutes of Health (NIH) in the United States. [Extracted from the article]

A recent report from the Russian Academy of Sciences discusses the development of anticancer drugs based on zinc-dependent histone deacetylase inhibitors (HDACi). The researchers focused on the selectivity and strength of inhibition of HDACi, which are important factors in determining their therapeutic action. They developed an in-cell high-throughput screening method using fluorogenic substrates to determine the selectivity of HDACi at the class level. However, they found that the additional inhibitory activity of HDACi against metallo-b-lactamase domain-containing protein 2 (MBLAC2) can lead to testing errors. This research provides valuable insights into the potential and limitations of this screening method. [Extracted from the article]

A study conducted by researchers at Keimyung University in South Korea has found that ginsenoside compound K (GCK) has anti-inflammatory effects in macrophages stimulated by ethanol. The study demonstrated that GCK activates sirtuin 1 (SIRT1) and estrogen receptor a (ERa), leading to the inhibition of inflammatory and oxidative stress genes and the reversal of M1 polarization in macrophages. The researchers concluded that GCK exhibits anti-inflammatory and antioxidant properties, which may counteract disruptions in energy metabolism caused by ethanol in macrophages. This research provides valuable insights into potential therapeutic applications of GCK in mitigating inflammation-related diseases. [Extracted from the article]

A recent study conducted at the Shenzhen Campus of Sun Yat-sen University has revealed new findings on nucleoproteins. The researchers developed a genetically encoded mTORC1 sensor called TORSEL, which can detect the inhibition of mTORC1 activity in living cells and tissues. Using TORSEL, the researchers identified histone deacetylase inhibitors that selectively block nutrient-sensing signaling to inhibit mTORC1. This research provides valuable insights into the development of therapeutic targets for diseases such as cancer, diabetes, aging, and neurodegeneration. [Extracted from the article]

A recent research study conducted by the University of Applied Sciences Darmstadt in Germany has provided new insights into nucleoproteins. The study focused on the kinetics and mechanism of drug binding to its target, which is crucial for pharmacological efficacy. The researchers developed a method to calculate concentration-dependent apparent rate constants for the inhibition or inactivation of human histone deacetylase 8 (HDAC8), a promising cancer target. The study classified certain compounds as fast reversible inhibitors, while others were identified as slow two-step inactivators or reversible inhibitors. This research contributes to a better understanding of nucleoproteins and their potential applications in drug development. [Extracted from the article]

Researchers at Mashhad University of Medical Sciences in Iran have conducted a study on the design, synthesis, and evaluation of chalcone-based compounds as potential HDAC inhibitors and anticancer agents. The compounds showed strong anti-proliferative activity against three cancer cell lines and low cytotoxicity on normal cells. One specific compound, 9d, demonstrated significant anti-proliferative activity against HCT-116 cancer cells and strong inhibition of HDAC1 enzyme activity. It also exhibited an anti-angiogenic effect and showed potential as a new potent HDAC inhibitor and anticancer agent. The research was supported by Mashhad University of Medical Sciences. [Extracted from the article]

A recent study conducted by researchers at the University of Phayao in Thailand explored the effects of a high-fat diet and exposure to Bisphenol A (BPA) on kidney health. The study found that rats fed a high-fat diet and exposed to BPA experienced renal dysfunction, oxidative stress, inflammation, and mitochondrial dysfunction. However, treatment with N-acetylcysteine (NAC) significantly improved these conditions. The researchers concluded that NAC may be beneficial in protecting against kidney damage caused by prolonged exposure to BPA and a high-fat diet. This study provides insights into potential therapeutic strategies for maintaining kidney health in the face of environmental and dietary challenges. [Extracted from the article]

A recent study conducted by investigators at Baylor University College of Medicine in Houston, Texas, explores the role of histone deacetylase 3 (HDAC3) in the regulation of kidney inflammation and fibrosis in chronic kidney disease (CKD). The researchers found that HDAC3 is induced in the kidneys of animal models with CKD, but mice with conditional HDAC3 deletion showed significantly reduced fibrosis compared to control mice. The study suggests that targeting HDAC3 could be a potential therapeutic strategy for CKD. The research has been peer-reviewed and published in Kidney International. [Extracted from the article]

A recent report from researchers at Keimyung University in South Korea explores the role of histone deacetylase 4 (HDAC4) in inflammatory and metabolic processes. HDAC4 is a class IIa HDAC that has potential as a therapeutic target for treating various biological pathways by deacetylating non-histone proteins, including transcription factors. The activity of HDAC4 is regulated at multiple levels, and its functions vary depending on the tissue and the factors and substrates involved. This review summarizes the regulatory modes of HDAC4 activity and its functions in inflammation, insulin signaling and glucose metabolism, and cardiac muscle development. [Extracted from the article]

A study conducted at Augusta University in Georgia explored the effects of hyperglycemia on human corneal epithelial cells. The researchers found that hyperglycemic conditions led to increased expression of inflammatory molecules and reactive oxygen species (ROS), which can delay corneal wound healing. They also discovered that histone deacetylase (HDAC) inhibition increased glycerol uptake in both normal and hyperglycemic conditions, suggesting that HDAC activity plays a role in regulating the function of the glycerol channel aquaporin-3 (AQP3). These findings provide insights into the potential mechanisms underlying delayed corneal wound healing in diabetes. [Extracted from the article]

A preprint abstract from biorxiv.org discusses the potential treatment strategy for diffuse midline gliomas (DMG), which are aggressive and fatal pediatric tumors of the central nervous system. The study focuses on the driver mutation H3-K27M, which reshapes the epigenetic landscape of these cells to promote tumorigenesis. The researchers examined the therapeutic potential of dual targeting of histone deacetylases (HDACs) and MYC in these tumors. The combination of the HDAC inhibitor Vorinostat and the inhibitor Sulfopin resulted in a substantial decrease in cell viability and downregulation of oncogenic pathways. In-vivo studies on mice also showed significant tumor growth reduction with this drug combination. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]